Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Amarant Pharmaceuticals Private Limited

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000584 145 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx145product presentations
G62generic molecules
DF12dosage-form groups
TA12therapeutic areas
PKR145current price records
REG120registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage90%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixAmarant Pharmaceuticals Private LimitedShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/amarant-pharmaceuticals-private-limitedGenerated 10 Aug 2026Anti-infectives55 · 38%CNS & mental health39 · 27%Cardiovascular18 · 12%Vitamins, minerals & nutrition10 · 7%Pain & musculoskeletal6 · 4%Endocrine & metabolic5 · 3%Gastrointestinal & hepatology4 · 3%Other therapeutic areas8 · 6%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioAmarant Pharmaceuticals Private LimitedDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/amarant-pharmaceuticals-private-limitedGenerated 10 Aug 2026145presentationsTablet86 · 59%Capsule19 · 13%Injection11 · 8%Syrup9 · 6%Suspension8 · 6%Solution4 · 3%Other forms8 · 6%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionAmarant Pharmaceuticals Private LimitedCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/amarant-pharmaceuticals-private-limitedGenerated 10 Aug 2026131comparable productsBelow market median27 · 21%Near market median48 · 37%Above market median56 · 43%Company median price position+3.9%Lowest-price equivalents11Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsAmarant Pharmaceuticals Private LimitedCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/amarant-pharmaceuticals-private-limitedGenerated 10 Aug 2026Mediate Pharmaceutical Pvt Ltd39 shared63% overlapBio-Labs(Pvt) Ltd33 shared53% overlapNeutro Pharma (Pvt.) Ltd.,33 shared53% overlapNabiqasim Industries (Pvt) Ltd.,32 shared52% overlapPharmasol (Pvt) Ltd.32 shared52% overlapGenome Pharmaceuticals (Pvt.) Ltd,32 shared52% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives55 products · 38%
CNS & mental health39 products · 27%
Cardiovascular18 products · 12%
Vitamins, minerals & nutrition10 products · 7%
Pain & musculoskeletal6 products · 4%
Endocrine & metabolic5 products · 3%
Gastrointestinal & hepatology4 products · 3%
Respiratory & allergy4 products · 3%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Antipsychotics20 products · 14%
Third-generation cephalosporins14 products · 10%
Antiepileptics14 products · 10%
Calcium-channel blockers13 products · 9%
Vitamins / minerals / hematinics10 products · 7%
Antimalarials9 products · 6%
Fluoroquinolone antibacterials8 products · 6%
Macrolide antibacterials7 products · 5%
Formulation footprint

Dosage forms

Tablet86 products
Capsule19 products
Injection11 products
Syrup9 products
Suspension8 products
Solution4 products
Cream2 products
Infusion2 products
Gel1 products
Lotion1 products
Ointment1 products
Pessary1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 NeorisRisperidone 7presentations 1 mg, 1 mg/mL, 2 mg, 3 mg · Tablet, Solution #2 AzirantAzithromycin 5presentations 200 mg/5 mL, 250 mg, 500 mg · Suspension, Capsule, Tablet #3 Listan AHAmlodipine + Valsartan + Hydrochlorothiazide 5presentations 10 mg + 160 mg + 12.5 mg, 10 mg + 160 mg + 25 mg, 10 mg + 320 mg + 25 mg, 5 mg + 160 mg + 12.5 mg · Tablet #4 VetrawinLevetiracetam 5presentations 100 mg/mL, 250 mg, 500 mg, 750 mg · Solution, Tablet #5 Amprexa-FOlanzapine + Fluoxetine 4presentations 12 mg + 25 mg, 6 mg + 25 mg · Capsule #6 AmtraxaCeftriaxone 4presentations 1 g, 250 mg, 500 mg · Injection
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median2721% of comparable products
Near market median48within ±5% of median
Above market median5643% of comparable products
Lowest-price equivalents11ties included
Company median price position +3.9% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Thicar SR 400 mgLithium carbonate · Sustained-release tablet · 10 x 10's PKR 4.88/tablet-77.5% vs market median Cefirant DS 200 mg/5 mLCefixime · Dry suspension · 60mL PKR 6.41/mL-50.1% vs market median Edper 5%Permethrin · Cream · 30 gm PKR 2.75/g-29.4% vs market median Chlorilex 4 mgChlorpheniramine · Tablet · 1000’s PKR 0.13/tablet-25.1% vs market median Lexitran 80 mg + 400 mgSulfamethoxazole + Trimethoprim · Tablet · 400's PKR 2.99/tablet-23.6% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Mediate Pharmaceutical Pvt Ltd239 products · 90 generics 39shared generics Bio-Labs(Pvt) Ltd234 products · 82 generics 33shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 33shared generics Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 32shared generics Pharmasol (Pvt) Ltd.251 products · 101 generics 32shared generics Genome Pharmaceuticals (Pvt.) Ltd,149 products · 71 generics 32shared generics
Regulatory & price activity

Observed database signals

Registration numbers120
Price-history records161
Products with price history15
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date23 Jul 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

13 results
Intelligence filter: Therapeutic areaCardiovascular Drug classCalcium-channel blockers Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Amlosyl Amlodipine 10 mg Tablet 20's 042065 PKR 410.99 PKR 20.55/tablet 18% above median
Listan AH Amlodipine 10 mg Tablet 28's 098552 PKR 511.44 PKR 18.27/tablet 5% above median
Listan AH Amlodipine + Valsartan + Hydrochlorothiazide 10 mg + 320 mg + 25 mg Tablet 14's 098554 PKR 393.40 PKR 28.10/tablet 7% above median
Listan AH Amlodipine + Valsartan + Hydrochlorothiazide 5 mg + 160 mg + 25 mg Tablet 14's 098553 PKR 238.85 PKR 17.06/tablet Near median
Listan AH Amlodipine + Valsartan + Hydrochlorothiazide 10 mg + 160 mg + 25 mg Tablet 14's 098552 PKR 255.71 PKR 18.27/tablet Near median
Listan AH Amlodipine + Valsartan + Hydrochlorothiazide 5 mg + 160 mg + 12.5 mg Tablet 14's 098555 PKR 233.23 PKR 16.66/tablet Near median
Listan AH Amlodipine 5 mg Tablet 28's 098555 PKR 466.47 PKR 16.66/tablet 55% above median
Listan AH Amlodipine 10 mg Tablet 28's 098556 PKR 505.81 PKR 18.06/tablet Near median
Listan AH Amlodipine + Valsartan + Hydrochlorothiazide 10 mg + 160 mg + 12.5 mg Tablet 14's 098556 PKR 252.91 PKR 18.07/tablet Near median
Listan AH Amlodipine 5 mg Tablet 28's 098553 PKR 477.71 PKR 17.06/tablet 58% above median
Listan AM Amlodipine + Valsartan 10 mg + 160 mg Tablet 14's 104418 PKR 609.27 PKR 43.52/tablet 7% below median
Listan AM Amlodipine + Valsartan 5 mg + 80 mg Tablet 14's 082248 PKR 469.85 PKR 33.56/tablet 6% above median
Listan AM Amlodipine 10 mg Tablet 28's 104418 PKR 1,218.56 PKR 43.52/tablet 150% above median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.